Blog
Original analysis of GLP-1 and peptide pricing, evidence and regulation — written to be useful to someone deciding what to do, not to rank for a keyword.
Every article here starts from a specific claim we think is wrong, or a fact we think is being withheld. Brand prices collapsed and comparison sites did not update. ODT products have no trial evidence and cost more than the injection. "Microdosing" appeared industry-wide the month enforcement discretion ended. Some platforms resell brand drugs at eleven times the manufacturer price. Each of these is checkable, and each is checked here.
CVS Caremark Restores Zepbound Coverage Oct 1, 2026: What to Do Now
CVS Caremark returns Zepbound to its commercial formularies on October 1, 2026, with copays as low as $25. The timeline, the employer opt-out catch, a…
Cost & Science · Jul 14, 2026Wegovy Pill (Oral Semaglutide 25 mg): Price, Trial Data & Who It Fits
The first oral GLP-1 for weight loss launched January 2026 at $149/month for the starting dose. OASIS 4 results, the real dose-by-dose pricing, and ho…
Coverage · Jul 14, 2026Medicare & GLP-1s in 2026: The $50 Bridge Pilot and the 2027 Price Cut
Two changes are rewriting Medicare GLP-1 access: the GLP-1 Bridge pilot ($50/month copays from July 1, 2026) and negotiated semaglutide prices of $274…
Science & Cost · Jul 14, 2026Foundayo (Orforglipron): Lilly's Oral GLP-1, Priced and Explained
Foundayo (orforglipron) is Eli Lilly's once-daily oral GLP-1, approved April 2026 with no food-timing restrictions. How it works, what it costs at lau…
Coverage & Science · Jul 14, 2026Zepbound for Sleep Apnea: The Coverage Door Most Patients Miss
Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity — a separate indication that opens insurance coverage e…
Science · Jul 14, 2026GLP-1s and Muscle Loss: What the Evidence Shows and How to Limit It
Roughly a quarter to a third of GLP-1 weight loss can come from lean mass. What the DEXA substudies actually show, why it matters for long-term health…
Science · Jul 14, 2026GLP-1 Weight Plateaus: Why They Happen and What Actually Works
Weight loss on semaglutide and tirzepatide flattens for almost everyone — the trials show exactly when. Why plateaus are physiology rather than failur…
Safety · Jul 14, 2026Counterfeit and Gray-Market GLP-1s: A Field Guide to Not Getting Hurt
Fake Ozempic pens, “research-use” semaglutide vials, and salt-form powders are the sharp edge of the GLP-1 boom. The verification chain that separates…
Access · Jul 14, 2026GLP-1 Prior Authorization and Appeals: The Playbook That Wins
Most GLP-1 denials fall into five categories, and three of them are winnable. The documentation that approvals actually turn on, the appeal sequence a…
Regulatory · Jul 14, 2026Is Compounded GLP-1 Still Legal in July 2026? The Honest Status
The shortages ended, the deadlines passed, and compounded semaglutide and tirzepatide are still for sale. What the law actually permits in mid-2026, w…
Brand GLP-1 prices collapsed. Most comparison sites still haven't
Zepbound fell to $299. Wegovy to $349. The oral tablet to $149. The price gap that justified compounded …
No trial has ever tested oral GLP-1 compounds. So why are they the
Compounded ODT tirzepatide and semaglutide have never been tested in a clinical trial — and they cost mo…
The $179 that is really $299: how introductory pricing works in GL
TrimRx advertises $179. MEDVi advertises $179. Both charge $299 from month two. Here is how first-month …
Why every GLP-1 provider suddenly sells 'microdosing'
The industry-wide pivot to microdosing tracks the end of FDA enforcement discretion almost exactly. That…
Eden sells Zepbound for $1,399. Lilly sells it for $299.
Some telehealth platforms resell brand-name GLP-1s at close to retail while the manufacturer sells the i…
Flat-rate vs dose-escalating GLP-1 pricing: a $3,000 difference
Some providers charge the same price at every dose. Others raise it as you titrate. Over a year, the gap…
Which GLP-1 providers charge no membership fee
Split billing makes programmes look cheaper than they are. Here is who charges a membership, who does no…
What a year of GLP-1 treatment actually costs
Monthly figures are how this is marketed. Annual totals are how it is experienced. Every provider, twelv…
Compounded or brand? The decision has changed
The compounded case rested on a price gap that has largely closed. Here is how to decide now.…
The cheap GLP-1 plan that caps your dose below the trial dose
Noom's $199 semaglutide is capped at 0.6mg. The STEP trials used 2.4mg. That is not a discount — it is a…
The LillyDirect 45-day rule that costs $250 if you are a week late
Zepbound's $449 maintenance rate holds only if you refill within 45 days of your last delivery. Miss it …
How to verify the pharmacy behind your GLP-1
The pharmacy matters more than the brand on the website. Seven questions, and what the answers tell you.…
Semaglutide sodium is not semaglutide
Some compounded products use semaglutide sodium or acetate. The FDA has said these are not the same acti…
1,700+ adverse events, and the vial that causes most of them
The FDA has logged 1,700++ adverse events for compounded semaglutide and 320+ for tirzepatide. Dosing er…
What happens when you stop taking a GLP-1
Extension data found roughly two-thirds of lost weight returned within a year of stopping. That changes …
Tirzepatide vs semaglutide: what the only head-to-head trial found
SURMOUNT-5 put them against each other directly: −20.2% vs −13.7%. Here is the result, and the two cavea…
The GLP-1 pathway that costs $25 a month
If your plan covers Zepbound or Wegovy, a manufacturer savings card can bring it to roughly $25. Nothing…
Three ways peptide marketing overstates the evidence
Mouse-to-human transfer, biomarker-for-outcome substitution, and deficiency-to-enhancement transfer. Onc…
NAD+: real biology, thin clinical evidence
NAD+ decline with age is well-established cell biology. That supplementing it reverses ageing in humans …
Do not pay a subscription for a cheap generic
Both are FDA-approved and available as inexpensive generics. Compounded troches and 'proprietary blends'…
How to use this section
Everything in this section is built on the same two commitments, and it is worth stating them before you read anything else.
Every price carries an evidence status. Verified means we hold a dated capture of the provider's own page. Reported — pending verification means a provider or a third party reports it and we have not captured it ourselves. Evaluation in progress means verification is pending and we are not asserting the fact. We do not upgrade a price to Verified because another comparison site published it — sites in this category contradict each other routinely, and a figure repeated by three affiliate blogs is still one unverified figure.
Every clinical claim traces to a primary source. FDA labels and guidance for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Patient forums are never used as evidence of price, safety or efficacy, and animal research is never presented as proof of a human clinical effect.
The context that applies to everything here
Three facts sit underneath every page in this section, and if you take nothing else from it, take these.
Brand prices collapsed, and most comparison sites have not updated. Brand Zepbound is now $299-$449 through LillyDirect. Brand Wegovy is $349 through NovoCare, and the oral Wegovy tablet is $149. Foundayo, Lilly's approved oral GLP-1, starts at $149. With commercial insurance that covers them, either brand can be roughly $25 a month. Against that, a compounded programme priced above $299 is charging more than the FDA-approved drug.
The legal basis for compounding these molecules narrowed sharply in 2025. The FDA declared both shortages resolved and enforcement discretion ended for every class of compounder between February and May 2025. The surviving route requires a prescriber to document a clinical difference for the individual patient — which is what "personalized dosing" and "microdose" programmes are, as a matter of regulatory mechanics rather than clinical innovation.
The trial evidence applies to injections. Every efficacy figure in this field — SURMOUNT, STEP, SELECT — comes from an FDA-approved subcutaneous injection. None of it was collected on a compounded preparation, a microdose, or an orally disintegrating tablet. The evidence is strong exactly where it was gathered and silent everywhere else.
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
Verified against Eli Lilly's own pricing pages. Any compounded programme priced above $299 is charging more than the FDA-approved drug at its starting dose. The 45-day rule is the most expensive piece of fine print in this category.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Tirzepatide carries a boxed warning for thyroid C-cell tumours, based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is not a precaution to weigh; it is a hard stop.
Serious but less common risks include pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury secondary to dehydration from vomiting or diarrhoea, diabetic retinopathy complications in people with existing retinopathy, and hypoglycaemia when combined with insulin or a sulfonylurea. Severe abdominal pain radiating to the back warrants urgent assessment for pancreatitis, not a message to a chat widget.
Before starting, a clinician should establish a baseline: weight and BMI, blood pressure, HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. During treatment, tolerance should be reviewed at each escalation step rather than escalated automatically on a calendar.
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
In SURMOUNT-4 — the randomised withdrawal trial — participants taken off tirzepatide after a 36-week lead-in regained roughly 14% of body weight over the following year, while those who continued lost a further ~5%. This is the trial that most changes the arithmetic of treatment, and it is almost never cited on a pricing page.
The consequence is financial as much as clinical. If holding the result requires holding the medication, then the figure that matters is not the introductory price, and not even the annual price. It is the indefinite monthly price. Anyone selecting a provider on the strength of a first-month rate is optimising the wrong variable entirely.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
These words are used interchangeably in marketing and they are not interchangeable at all. The distinction decides what evidence applies to what you are actually buying.
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded tirzepatide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.